We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-6.97%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.62B
AUM Growth
-$52.9M
Cap. Flow
+$108M
Cap. Flow %
4.11%
Top 10 Hldgs %
34.14%
Holding
89
New
20
Increased
21
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$86.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$43M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.7M
4
ABBV icon
AbbVie
ABBV
+$37.6M
5
VEEV icon
Veeva Systems
VEEV
+$37.2M

Top Sells

Rank Stock Value
1
OM icon
Outset Medical
OM
+$128M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$34.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.4M
4
HRTX icon
Heron Therapeutics
HRTX
+$20.1M
5
HCA icon
HCA Healthcare
HCA
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.59%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
76
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.46M 0.09%
801,204
+70,847
+10% +$433K
CCCC icon
77
C4 Therapeutics
CCCC
$385M
– –
-284,772
Closed -$6.91M
DXCM icon
78
DexCom
DXCM
$31.5B
– –
-148,084
Closed -$18.9M
GILD icon
79
CALL
Gilead Sciences
GILD
$162B
– –
-1,412,500
Closed -$84M
GILD icon
80
Gilead Sciences
GILD
$162B
– –
-249,884
Closed -$14.9M
HCA icon
81
HCA Healthcare
HCA
$87.2B
– –
-80,128
Closed -$20.1M
HRTX icon
82
Heron Therapeutics
HRTX
$93.9M
– –
-3,512,348
Closed -$20.1M
LAB icon
83
Standard BioTools
LAB
$340M
– –
-980,505
Closed -$3.52M
OM icon
84
Outset Medical
OM
$84.7M
– –
-187,379
Closed -$128M
CANO
85
DELISTED
Cano Health, Inc.
CANO
– –
-13,019
Closed -$8.27M
SRRA
86
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,062,888
Closed -$34.1M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2022 Portfolio in Review

As of Q2 2022, PFM Health Sciences held 89 positions worth $2.62B, down 2% from $2.67B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $108M of net new capital in Q2 2022, opening 20 new positions and adding to 21 existing holdings. Its largest new stake was Merck: 971,998 shares worth $88.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Syndax Pharmaceuticals, an estimated $24.4M trimmed.

  • PFM Health Sciences's largest Q2 2022 buy was Merck: 971,998 shares worth $88.6M.
  • PFM Health Sciences added most to uniQure in Q2 2022, an estimated $27.1M increase.
  • PFM Health Sciences's biggest Q2 2022 reduction was Syndax Pharmaceuticals, cutting an estimated $24.4M.
  • PFM Health Sciences fully exited Outset Medical in Q2 2022, selling an estimated $128M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $2.62B portfolio in Q2 2022.
  • PFM Health Sciences opened 20 new positions and closed 10 in Q2 2022.
  • PFM Health Sciences's portfolio value fell 2% quarter-over-quarter to $2.62B.

Based on PFM Health Sciences's 13F filing for Q2 2022, filed 15 Aug 2022.